Gottingen, Germany

Olaf Heindenreich


Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 72(Granted Patents)


Company Filing History:


Years Active: 1997-1998

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Olaf Heindenreich

Introduction

Olaf Heindenreich is a notable inventor based in Göttingen, Germany. He has made significant contributions to the field of RNA technology, particularly in the development of modified ribozymes. His work has implications for therapeutic applications and biocatalysis.

Latest Patents

Heindenreich holds 2 patents related to RNA molecules with catalytic activity. His latest patents include innovations in modified ribozymes. The first patent claims RNA molecules that incorporate at least one modified nucleoside, where the hydroxy group at the 2'-position of the ribose sugar is replaced by a modifier group. This modifier group can be an halo, amino, mono- or disubstituted amino, or an azido group, with methods of use in vivo. The second patent refers to RNA molecules with catalytic activity that also feature modified nucleosides, where the hydroxy group at the 2'-position is replaced by various modifier groups, including halo, sulfhydryl, azido, and amino groups. This invention outlines a process for preparing modified RNA molecules and their use as therapeutic agents and biocatalysts.

Career Highlights

Heindenreich is affiliated with the Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V., a prestigious research organization in Germany. His work has been instrumental in advancing the understanding of RNA functionality and its potential applications in medicine.

Collaborations

He has collaborated with notable scientists such as Fritz Eckstein and Wolfgang A. Pieken, contributing to the advancement of RNA research through teamwork and shared expertise.

Conclusion

Olaf Heindenreich's innovative work in the field of modified ribozymes showcases his significant contributions to RNA technology. His patents reflect a commitment to advancing scientific knowledge and practical applications in biomedicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…